According to a recent LinkedIn post from Hemanext, the company recently polled clinicians on whether fresher red blood cell units may function better for certain patients, such as those requiring chronic transfusions. The post notes that red blood cells naturally degrade during storage, with losses in ATP, 2,3-DPG, and cellular flexibility cited from published studies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that hypoxic red blood cell technology is presented as a way to help preserve these qualities across the storage period and potentially narrow functional differences between younger and older blood units. This approach is positioned as the basis of Hemanext ONE®, described as the first and only FDA-authorized and CE-marked hypoxic blood storage system, which may strengthen the platform’s regulatory differentiation.
As shared in the post, Hemanext ONE® is designed to process and store red blood cells under low-oxygen conditions to decrease oxygen-driven degradation, drawing on multiple referenced scientific publications. For investors, the emphasis on clinician feedback, clinical science, and regulatory credentials suggests an effort to build medical community adoption, which could support future revenue growth if the technology gains broader utilization in transfusion medicine.
The focus on chronic transfusion patients implies a potentially specialized but clinically intensive market segment where improved product performance could command pricing power or preferential use. If Hemanext can convert this scientific and regulatory positioning into hospital contracts and blood center partnerships, the platform could enhance the company’s competitive standing versus conventional storage technologies and contribute to longer-term commercialization prospects.